Bis(μ-5-hydr­oxy-2-{[2-(N-phenyl­thio­carbamo­yl)hydrazin-1-yl­idene]meth­yl}phenolato)bis[chloridozinc(II)] N,N-dimethyl­formamide tetra­solvate

In the dinuclear title compound, [Zn2(C14H12N3O2S)2Cl2]·4C3H7NO, the two monodeprotonated Schiff base ligands N,O,S:O-chelate to Zn atoms. The formally negatively charged O atom involved in chelation also serves as a bridge. The O, O′, N and S atoms comprise a square, and the Cl atom the apex of a square pyramid surrounding each metal atom. The solvate dimethyl­formamide mol­ecules, one of which is disordered over two positions in a 3:1 ratio, are hydrogen bonded to the dinuclear mol­ecule

(2,2′-Bipyridine-κ2 N,N′)(4-hydr­oxy-2-oxidobenzaldehyde thio­semicar­ba­zon­ato-κ3 O 2,N 1,S)zinc(II)

The ZnII atom in the title compound, [Zn(C8H7N3O2S)(C10H8N2)], is N,N′-chelated by the heterocycle and N,O,S-chelated by the doubly deprotonated Schiff base ligand in a distorted square-pyramidal environment. O—H⋯O and N—H⋯N hydrogen bonds link adjacent mol­ecules into a layer structure

Bis(μ-4-hydr­oxy-2-oxidobenzaldehyde 4-ethyl­thio­semicarbazone)-κ4 O 2,N 1,S:O 2;κ4 O 2:O 2,N 1,S-bis­[chloridozinc(II)] dimethyl sulfoxide tris­olvate

The two ZnII atoms in the title compound, [Zn2(C10H12N3O2S)2Cl2]·3C2H6OS, are each N,O,S-chelated by a mono-deprotonated Schiff base ligand. The Zn atoms are bridged through the phenolate O atom, leading to a central Zn2O2 core. Each Zn atom has a Cl atom in the apical position of a distorted square-pyramidal environment. Hydr­oxy–DMSO (DMSO is dimethyl sulfoxide) O—H⋯O and amide–DMSO N—H⋯O hydrogen bonds link the components of the crystal structure. Two of the DMSO mol­ecules are partially disordered, with each modelled over two sites of equal weight

{2-[(2-Carbamothiol­ylhydrazin-1-yl­idene-κ2 N 1,S)meth­yl]-6-hy­droxy­phenolato-κO 1}(triphenyl­phosphine-κP)nickel(II) chloride

The deprotonated Schiff base ligand in the title compound, [Ni(C8H8N3O2S)(C18H15P)]Cl, functions as an N,O,S-chelating anion to the phosphine-coordinated Ni atom, which exists in a distorted square-planar geometry. The hy­droxy group forms an intra­molecular O—H⋯O hydrogen bond. The two amino groups of the cation are hydrogen-bond donors to the chloride anion; the hydrogen bonds generate a chain structure running along the b axis

Chlorido(2-methyl-4-oxo-4H-pyran-3-olato-κ 2 O 3,O 4)(1,10-phenanthroline-κ 2 N,N′)copper(II)

The copper(II) atoms in the two independent mol­ecules of the title compound, [Cu(C6H5O3)Cl(C12H8N2)], both adopt square-pyramidal geometries. The two coordinating atoms of the two heterocyclic ligands comprise the square plane, and the chlorine atom occupies the apical position of the coordination environment

Bis[(4-chloro­benz­yl)triphenyl­phospho­nium] tetra­chloridozincate(II) trihydrate

The crystal structure of the title compound, (C25H21ClP)2[ZnCl4]·3H2O, consists of tetra­hedral phosphonium cations and tetra­hedral zincate anions; the water mol­ecules form weak hydrogen bonds to the anions. Two of the water mol­ecules are disordered over three sites in a 0.68:0.55:0.77 ratio

[1-(4-Hydr­oxy-2-oxidobenzyl­idene)-4-phenyl­thio­semicarbazonato-κ3 N,O,S](1,10-phenanthroline-κ2 N,N′)zinc(II)–4,4′-bipyridine (2/1)

The ZnII atom in the title compound, [Zn(C14H11N3O2S)(C12H8N2)]·0.5C10H8N2, is N,N′-chelated by the N-heterocycle and N,O,S-chelated by the deprotonated Schiff base in a square-pyramidal environment. The hydr­oxy group of the Schiff base is a hydrogen-bond donor to 4,4′-bipyridine, which is located about a center of inversion, resulting in the formation of a supra­molecular trimeric unit

Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities

The aim of this pilot study was to examine the relationship between clinical response, adverse effects, sertraline (SERT) plasma concentrations and the genetic polymorphism of the serotonin transporter gene-linked polymorphic region (5HTTLPR) in 2 ethnic patient groups. The study involved 45 patients in a clinical trial who received a fixed dose regimen of 50 mg SERT for one week, then a variable-dose regimen for a further 6 weeks for major depressive disorder. At weeks 1 and 6, the following assessments were completed: Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI), drug adverse reaction scale and measurement of plasma SERT levels. Genomic analysis for the long and short allele variants of the 5HTTLPR polymorphism was also carried out. Caucasian subjects had a higher rate of l/l genotype while Chinese subjects had higher frequencies of l/s and s/s genotypes. Comparison of the subjects with the 5HTTLPR s/s genotype and those with the l/l and l/s genotypes found no significant differences in the HDRS scores, CGI scores, response rates, adverse effects and SERT plasma concentrations at week 6

3,4-Dimethyl-N-(2,4,5-trimeth­oxy­benzyl­idene)-1,2-isoxazol-5-amine

In the title compound, C15H18N2O4, the aromatic rings on the azomethine double bond are trans to each other [C—C=N—C torsion angle = −178.29 (12)°] and they are approximately coplanar, the dihedral angle between them being 5.0 (1)°

N-[4-(Dimethyl­amino)­benzyl­idene]-3,4-dimethyl­isoxazol-5-amine

The aromatic rings attached to the azomethine double bond in the title compound, C14H17N3O, are trans to each other [C—C=N—C torsion angle = 179.5 (1)°], and they are approximately coplanar [dihedral angle between the five- and six-membered rings = 13.7 (1)°]